HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status : vimarsana.com

— NDA accepted and both fruquintinib and sintilimab granted Priority Review, following Breakthrough Therapy designation in July 2023 — — First regulatory filing for fruquintinib for use in...

Related Keywords

Hong Kong , Shanghai , China , Hui Zhou , Guangdong , Macau , United States , American , Daphne Zhang , Eli Lilly , Ben Atwell Alex Shaw , Adimab Incyte , Freddy Crossley , Michael Shi , Zhou Yi , Atholl Tweedie , Stock Exchange Of Hong Kong , China Limited , Md Anderson Cancer Center , China National Reimbursement Drug List , Linkedin , Exchange Commission , Innovent Biologics Inc , China National Medical Products Administration , Journal Of The American Medical Association , Nasdaq , Priority Review , Breakthrough Therapy , Innovent Biologics , New Drug Application , Chief Medical Officer , Senior Vice President , Fruquintinib Approval , American Medical Association , Securities Litigation Reform Act , Stock Exchange , Alex Shaw , Mismatch Repair , Global Cancer Observatory , World Fact , Accessed June , China Fact , Practice Guidelines , Markets ,